PEPG Share Price Performance
US$4.26
-0.73 (-14.63%)
Price US$4.26
Share Pricen/a
PepGen Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
PEPG Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
PepGen Inc. Key Details
About PEPG
- Founded
- 2018
- Employees
- 62
- CEO
- WebsiteView website
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
